Peer-reviewed veterinary case report
Benazepril improves heart function in cats with early hypertrophic
By Taillefer, Mylène & Di Fruscia, Rocky·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2006·Small Animal Veterinary Teaching Hospital·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study.
- Species:
- cat
Plain-English summary
A group of 21 cats with a heart condition called hypertrophic cardiomyopathy (HCM) was treated with either benazepril or diltiazem to see if it would improve their heart function. After six months, the cats receiving benazepril showed some improvement in heart function measurements, while those on diltiazem did not show any significant changes. However, the differences observed in the benazepril group might not be significant enough to confirm its effectiveness. More research is needed to fully understand how benazepril affects cats with this condition.
People also search for: cat heart disease treatment · hypertrophic cardiomyopathy in cats · benazepril for cats heart condition
Abstract
Twenty-one cats with hypertrophic cardiomyopathy were enrolled in this study to determine if the administration of benazepril (0.5 mg/kg body weight [BW], PO, q24h) to cats with subclinical hypertrophic cardiomyopathy improves cardiac diastolic function and reverses left ventricular hypertrophy when compared with diltiazem controlled delivery (CD) (10 mg/kg BW, PO, q24h). Cats were evaluated at day 0 and after 3 and 6 months of therapy. In the benazepril group (n = 11), the diastolic transmitral flow of the E and A waves ratio (E/A ratio) increased significantly between 0 and 6 months (P = 0.009) and the thickness of the left ventricular free wall in systole (LVFWs) decreased significantly between 0 and 3 months (P = 0.04). In the diltiazem CD group (n = 5), none of the parameters varied significantly throughout the study. There was no difference between the benazepril and the diltiazem CD group throughout the study. Therefore, the variations observed for the E/A ratio and the LVFWs may have been incidental. Further studies will be needed to establish the role of benazepril in subclinical hypertrophic cardiomyopathy in cat.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16734369/